Cargando…
Deep phenotyping for precision medicine in Parkinson's disease
A major challenge in medical genomics is to understand why individuals with the same disorder have different clinical symptoms and why those who carry the same mutation may be affected by different disorders. In every complex disorder, identifying the contribution of different genetic and non-geneti...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Company of Biologists Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178512/ https://www.ncbi.nlm.nih.gov/pubmed/35647913 http://dx.doi.org/10.1242/dmm.049376 |
_version_ | 1784723075583967232 |
---|---|
author | Schalkamp, Ann-Kathrin Rahman, Nabila Monzón-Sandoval, Jimena Sandor, Cynthia |
author_facet | Schalkamp, Ann-Kathrin Rahman, Nabila Monzón-Sandoval, Jimena Sandor, Cynthia |
author_sort | Schalkamp, Ann-Kathrin |
collection | PubMed |
description | A major challenge in medical genomics is to understand why individuals with the same disorder have different clinical symptoms and why those who carry the same mutation may be affected by different disorders. In every complex disorder, identifying the contribution of different genetic and non-genetic risk factors is a key obstacle to understanding disease mechanisms. Genetic studies rely on precise phenotypes and are unable to uncover the genetic contributions to a disorder when phenotypes are imprecise. To address this challenge, deeply phenotyped cohorts have been developed for which detailed, fine-grained data have been collected. These cohorts help us to investigate the underlying biological pathways and risk factors to identify treatment targets, and thus to advance precision medicine. The neurodegenerative disorder Parkinson's disease has a diverse phenotypical presentation and modest heritability, and its underlying disease mechanisms are still being debated. As such, considerable efforts have been made to develop deeply phenotyped cohorts for this disorder. Here, we focus on Parkinson's disease and explore how deep phenotyping can help address the challenges raised by genetic and phenotypic heterogeneity. We also discuss recent methods for data collection and computation, as well as methodological challenges that have to be overcome. |
format | Online Article Text |
id | pubmed-9178512 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Company of Biologists Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-91785122022-06-09 Deep phenotyping for precision medicine in Parkinson's disease Schalkamp, Ann-Kathrin Rahman, Nabila Monzón-Sandoval, Jimena Sandor, Cynthia Dis Model Mech Review A major challenge in medical genomics is to understand why individuals with the same disorder have different clinical symptoms and why those who carry the same mutation may be affected by different disorders. In every complex disorder, identifying the contribution of different genetic and non-genetic risk factors is a key obstacle to understanding disease mechanisms. Genetic studies rely on precise phenotypes and are unable to uncover the genetic contributions to a disorder when phenotypes are imprecise. To address this challenge, deeply phenotyped cohorts have been developed for which detailed, fine-grained data have been collected. These cohorts help us to investigate the underlying biological pathways and risk factors to identify treatment targets, and thus to advance precision medicine. The neurodegenerative disorder Parkinson's disease has a diverse phenotypical presentation and modest heritability, and its underlying disease mechanisms are still being debated. As such, considerable efforts have been made to develop deeply phenotyped cohorts for this disorder. Here, we focus on Parkinson's disease and explore how deep phenotyping can help address the challenges raised by genetic and phenotypic heterogeneity. We also discuss recent methods for data collection and computation, as well as methodological challenges that have to be overcome. The Company of Biologists Ltd 2022-06-01 /pmc/articles/PMC9178512/ /pubmed/35647913 http://dx.doi.org/10.1242/dmm.049376 Text en © 2022. Published by The Company of Biologists Ltd https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. |
spellingShingle | Review Schalkamp, Ann-Kathrin Rahman, Nabila Monzón-Sandoval, Jimena Sandor, Cynthia Deep phenotyping for precision medicine in Parkinson's disease |
title | Deep phenotyping for precision medicine in Parkinson's disease |
title_full | Deep phenotyping for precision medicine in Parkinson's disease |
title_fullStr | Deep phenotyping for precision medicine in Parkinson's disease |
title_full_unstemmed | Deep phenotyping for precision medicine in Parkinson's disease |
title_short | Deep phenotyping for precision medicine in Parkinson's disease |
title_sort | deep phenotyping for precision medicine in parkinson's disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178512/ https://www.ncbi.nlm.nih.gov/pubmed/35647913 http://dx.doi.org/10.1242/dmm.049376 |
work_keys_str_mv | AT schalkampannkathrin deepphenotypingforprecisionmedicineinparkinsonsdisease AT rahmannabila deepphenotypingforprecisionmedicineinparkinsonsdisease AT monzonsandovaljimena deepphenotypingforprecisionmedicineinparkinsonsdisease AT sandorcynthia deepphenotypingforprecisionmedicineinparkinsonsdisease |